-
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory
Lifestyle Content
Technology
-
50 photos that show the beauty of America’s national parks
-
The big summer trip is getting harder to pull off. What families are doing instead.
-
The AI trend that’s making financial advisors better at their jobs
-
The future of compensation management: Trends in technology that will shape 2026
-
US host cities made transit improvements a World Cup goal
Entertainment
-
Founder of FrienHund, Delivers Speech at Interzoo, Unveils Critical Strategies for Sustainable Global Pet E-commerce
-
The Thornton Team Closes Over $10 Million in April, Maintains #1 Position in Wheaton Real Estate Market
-
Anita Mai Tan Creations Introduces The Silver Road of Love: A US$1.3 Million Jeweled Heirloom of Love and Legacy
-
Digitech Services Expands India Operations with New Bengaluru Office
-
PriusMED releases updated medCLOUD 2026 platform for Enhanced Clinical Collaboration
Health
-
Global Aerospace’s Annual Jetstream Publication Provides An Introduction to Litigation Funding
-
3PL Service Netherlands Launches “Shopify EU Express Setup” to Get US and UK Brands Selling in Europe in Weeks, Not Months
-
Next Gen Contracting Expands Presence With Newly Opened Medford Office
-
Product Air Earns Elite Diamond Status: Mitsubishi Recognizes Company in Highest Category Held by Fewer Than 5% of Contractors Nationwide
-
Ryan’s Home Services Reaches Major Milestone with 32,000 Completed Work Orders
